New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

Amiselimod Shows Promise for Mild to Moderate UC in Phase 2 Study

The investigational oral drug amiselimod outperformed placebo at controlling mild to moderate UC symptoms with no ...

OCTOBER 9, 2024

Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk

In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...

DECEMBER 29, 2023

FDA Approves S1P Receptor Modulator for Moderate to Severe UC

The FDA has approved etrasimod (Velsipity, Pfizer), a selective sphingosine-1-phosphate receptor modulator, for ...

OCTOBER 13, 2023

Meta-Analysis Shows Efficacy of Advanced Orals in IBD

Treatment with a JAK inhibitor or S1P modulator increased remission in patients with UC, and JAK inhibitors are ...

MARCH 7, 2023

Excitement, Caution Greet Early Data For Etrasimod, Oral Agent for UC

The selective, oral sphingosine 1-phosphate receptor modulator etrasimod was significantly more effective than ...

MAY 24, 2019